Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DESFLURANE vs FLUOTHANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.
Halothane enhances GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and decreased excitability. It also potentiates glycine receptor function and disrupts synaptic transmission via interaction with voltage-gated sodium channels.
Maintenance of general anesthesia for inpatient and outpatient surgery in adults and children,Induction of anesthesia in adults and pediatric patients
Induction and maintenance of general anesthesia,Off-label: Use for status asthmaticus (rarely)
Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).
Induction: 0.5-3% halothane in oxygen or nitrous oxide/oxygen; maintenance: 0.5-1.5%.
Terminal elimination half-life is 3.5–4.5 minutes (context-sensitive half-life after prolonged anesthesia can be longer due to distribution, but true elimination is rapid due to low blood/gas partition coefficient).
Terminal elimination half-life is biphasic: initial 2-5 minutes (rapid redistribution), terminal 15-20 hours for trace amounts in adipose tissue due to slow release; contextually, emergence from anesthesia occurs within minutes.
Minimal hepatic metabolism (<0.02%) via CYP2E1; primarily eliminated unchanged by the lungs.
Hepatic metabolism via cytochrome P450 enzymes (CYP2E1 major, CYP2A6 minor) to trifluoroacetic acid, chloride, and bromide ions; reductive metabolism under hypoxic conditions produces potentially hepatotoxic intermediates.
Primarily eliminated via exhalation; minimal hepatic metabolism (<0.02%). Renal excretion of metabolites negligible. >99% excreted unchanged by lungs.
Primarily exhaled unchanged via the lungs; negligible renal (0.5% as metabolites) and fecal elimination.
Approximately 5–10% bound to plasma proteins (primarily albumin).
~40-50% bound to albumin.
Vd approximately 0.2–0.5 L/kg (small, reflecting limited tissue distribution; consistent with lipophilic but rapidly equilibrating profile).
2-5 L/kg; indicates extensive tissue distribution, particularly in adipose and brain.
Inhalation: ~100% bioavailable into systemic circulation via lungs.
Inhalation: 100% (administered as gas); no other relevant routes.
No dosage adjustment required for renal impairment; desflurane is minimally metabolized and not dependent on renal excretion.
No dose adjustment required for renal impairment; halothane is minimally excreted renally.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential for increased hepatotoxicity, but no dose modification guidelines exist.
Contraindicated in patients with Child-Pugh class B or C cirrhosis due to risk of hepatotoxicity; use with caution in mild impairment with reduced doses.
Induction: 3-12% inhaled (up to 18% for mask induction); maintenance: 3-6% inhaled; adjust based on age and response; higher MAC requirements in infants.
Induction: 0.5-2% halothane in oxygen; maintenance: 0.3-1%. Dose based on response.
Reduce dose by 20-30% compared to younger adults; typical maintenance 2-5% inhaled; lower MAC (approx 4.5% at 65 years); monitor for hypotension and bradycardia.
Reduce induction concentration to 0.5-1% and maintenance to 0.5% due to increased sensitivity and slower clearance.
Desflurane is not indicated for induction of general anesthesia in pediatric patients due to a high incidence of laryngospasm and upper airway adverse events.
Halothane is associated with a risk of life-threatening hepatic injury, including fatal hepatic necrosis, primarily following repeated exposure or in patients with known hypersensitivity. It should be avoided in patients with a history of unexplained jaundice or fever after halothane administration.
Malignant hyperthermia,Respiratory depression and airway complications,Cardiovascular depression (hypotension, bradycardia),QT prolongation,Hepatotoxicity (rare),Rising carbon monoxide levels with dry absorbents,Neurotoxicity in pediatric patients,Renal toxicity (rare)
Risk of hepatic necrosis (especially with repeated use); malignant hyperthermia; respiratory depression; hypotension; cardiac arrhythmias (including sensitization to catecholamines); increased intracranial pressure; requires trained personnel and monitoring; use caution in patients with hepatic disease.
Known sensitivity to desflurane or other halogenated anesthetics,History of malignant hyperthermia,Refractory hypovolemia,Increased intracranial pressure (relative),Concomitant use with adrenergic agents (risk of arrhythmias)
Known hypersensitivity to halothane or other halogenated anesthetics; history of unexplained jaundice or fever after halothane administration; suspected or known hepatic injury from halogenated anesthetics; risk of malignant hyperthermia (including family history).
No known food interactions. However, patients should follow preoperative fasting guidelines (nil per os for at least 2 hours for clear liquids and 6-8 hours for solid foods) to reduce the risk of pulmonary aspiration during anesthesia.
No specific food interactions known, but fasting is required preoperatively to prevent aspiration pneumonitis caused by relaxation of the lower esophageal sphincter and loss of airway reflexes.
Desflurane is not associated with major congenital malformations in the first trimester, but use in the second and third trimesters may cause fetal depression, decreased fetal heart rate variability, and neonatal respiratory depression. It is pregnancy category B, but caution is advised.
FDA Pregnancy Category C. First trimester: Increased risk of congenital anomalies (cleft palate, skeletal defects) in animal studies; avoid unless essential. Second and third trimesters: Prolonged exposure may cause neonatal respiratory depression, hypotonia, and thermoregulatory instability; risk of fetal hypoxia due to maternal hypotension.
Desflurane is minimally excreted into breast milk; M/P ratio is unknown. It is considered compatible with breastfeeding due to rapid elimination from the mother and low oral bioavailability in the infant. However, monitor for neonatal sedation.
Halothane is excreted in breast milk in low concentrations. M/P ratio not determined. Short-term use is considered compatible with breastfeeding; avoid prolonged or repeated exposure. Monitor infant for sedation and feeding difficulties.
No specific dose adjustment for desflurane in pregnancy, but the minimum alveolar concentration (MAC) is reduced by approximately 25-40% due to increased progesterone and other factors. Lower doses may be required to achieve desired anesthetic depth.
Increased sensitivity to myocardial depression; reduce dose by 25-50% in pregnant patients. Monitor closely for hypotension. No specific pharmacokinetic adjustments required due to pregnancy, but consider decreased MAC (minimum alveolar concentration) in late pregnancy.
Desflurane has the lowest blood-gas partition coefficient among volatile anesthetics, resulting in the fastest onset and emergence. Its pungent odor limits use for inhalation induction, especially in children. Due to its high vapor pressure, a specialized heated vaporizer is required. Desflurane can cause sympathetic nervous system activation at high concentrations, leading to tachycardia and hypertension. It is metabolized minimally (0.02%), but can produce carbon monoxide when exposed to dried CO2 absorbents; desiccated absorbents should be avoided. Malignant hyperthermia risk is present, so dantrolene should be available.
Halothane is a potent inhalational anesthetic with low blood-gas solubility, allowing rapid induction and emergence. It sensitizes the myocardium to catecholamines, increasing risk of arrhythmias, especially with epinephrine use. Halothane can cause hepatic necrosis, particularly with repeated exposure (halothane hepatitis). Avoid in patients with unexplained jaundice after prior halothane use. Use low concentrations with spontaneous ventilation to prevent respiratory depression.
You will receive desflurane gas through a mask or breathing tube to keep you asleep during surgery.,Desflurane has a strong smell; you may notice an odor as you fall asleep.,You will wake up quickly after the anesthetic is stopped, but you may feel drowsy or confused initially.,Potential side effects include nausea, vomiting, shivering, and a temporary increase in heart rate or blood pressure.,Inform your doctor if you have a personal or family history of malignant hyperthermia (a severe reaction to anesthesia).,Do not eat or drink before surgery as instructed to prevent aspiration.
Avoid food or drink for at least 6-8 hours before surgery to reduce aspiration risk.,Report any history of liver disease or allergic reactions to anesthesia.,You may experience shivering or nausea after waking up from anesthesia.,Do not drive or operate machinery for at least 24 hours after anesthesia.,Inform your doctor if you notice yellowing of skin or eyes, dark urine, or severe fatigue after surgery.
"Concurrent use of buspirone and desflurane may potentiate the hypotensive and bradycardic effects of desflurane, increasing the risk of hemodynamic instability during anesthesia induction or maintenance. Buspirone's serotonergic activity can also lower seizure threshold, potentially interacting with the anesthetic properties of desflurane to cause perioperative seizures or arrhythmias. Clinically, this combination requires careful cardiovascular monitoring and dose adjustment of desflurane to avoid excessive hypotension, bradycardia, or delayed emergence."
"Concomitant use of Desflurane and Triprolidine may lead to enhanced central nervous system (CNS) depression and potential respiratory compromise. Desflurane, a volatile anesthetic, depresses the CNS and respiratory drive, while Triprolidine, a first-generation antihistamine, adds sedative and anticholinergic effects. This synergistic interaction increases the risk of excessive sedation, hypotension, and respiratory depression, particularly during induction or recovery from anesthesia. Clinically, patients may experience prolonged emergence, worsened cognitive function, and increased need for ventilatory support."
"Concomitant administration of desflurane, a volatile halogenated anesthetic, with oxprenolol, a non-selective beta-adrenergic receptor antagonist with intrinsic sympathomimetic activity, can lead to additive negative inotropic and chronotropic effects on the myocardium, resulting in significant hypotension and bradycardia. This interaction occurs because desflurane depresses myocardial contractility and heart rate directly, while oxprenolol blocks compensatory sympathetic responses, potentially compromising cardiac output and tissue perfusion. Clinicians should be vigilant for exaggerated cardiovascular depression, especially during induction or changes in anesthetic depth."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DESFLURANE vs FLUOTHANE, answered by our medical review team.
DESFLURANE is a General Anesthetic that works by Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.. FLUOTHANE is a General Anesthetic that works by Halothane enhances GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and decreased excitability. It also potentiates glycine receptor function and disrupts synaptic transmission via interaction with voltage-gated sodium channels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DESFLURANE and FLUOTHANE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DESFLURANE is: Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).. The standard adult dose of FLUOTHANE is: Induction: 0.5-3% halothane in oxygen or nitrous oxide/oxygen; maintenance: 0.5-1.5%.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DESFLURANE and FLUOTHANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DESFLURANE is classified as Category C. Desflurane is not associated with major congenital malformations in the first trimester, but use in the second and third trimesters may cause fetal depression, decreased fetal hear. FLUOTHANE is classified as Category C. FDA Pregnancy Category C. First trimester: Increased risk of congenital anomalies (cleft palate, skeletal defects) in animal studies; avoid unless essential. Second and third trime. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.